Adrian Senderowicz, M.D.
Serving as Constellation Pharmaceuticals’ senior vice president and chief medical officer, Dr. Adrian Senderowicz is a board-certified medical oncologist with more than two decades of experience in the life sciences. As the principal investigator for a multitude of clinical trials in solid and hematological tumors, Adrian has significant regulatory expertise, including acting as a former clinical team leader at the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) Division of Drug Oncology Products. Prior to joining Constellation, Adrian served as chief medical officer at Cerulean Pharma, where he helped secure fast-track designation for the company’s lead clinical development program in two indications. Previously, Adrian held roles of increasing responsibility at Ignyta, Inc., Sanofi Oncology, Tokai Pharmaceuticals and AstraZeneca plc. He began his career as an investigator at the National Cancer Institute before joining the FDA’s CDER. Adrian completed his Internal Medicine residency training at the Icahn School of Medicine at Mount Sinai and a Clinical Oncology Fellowship at the NCI. He holds an M.D. degree from the School of Medicine at the Universidad de Buenos Aires in Argentina.